Unknown

Dataset Information

0

Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes.


ABSTRACT: Viral diversity is a challenge to the development of a hepatitis C virus (HCV) vaccine. Following vaccination of humans with adenoviral vectors, we determined the capacity of T cells to target common viral variants at immundominant epitopes ex vivo. We identified two major variants for epitopes NS3(1073) and NS3(1446), and multiple variants for epitope NS3(1406) that occurred in >5% of genotype 1 and 3 sequences at a population level. Cross-reactivity of vaccine-induced T cells was determined using variant peptides in IFN-? ELISPOT assays. Vaccine-induced T cells targeted approximately 90% of NS3(1073) genotype 1 sequences and 50% of NS3(1446) genotype 1 and 3 sequences. For NS3(1406), 62% of subtype-1b sequences were targeted. Next, we assessed whether an in vitro priming system, using dendritic cells and T cells from healthy donors, could identify a variant of NS3(1406) that was maximally cross-reactive. In vitro priming assays showed that of those tested the NS3(1406) vaccine variant was the most immunogenic. T cells primed with genotype 1 variants from subtype 1a or 1b were broadly cross-reactive with other variants from the same subtype. We conclude that immunization with candidate HCV adenoviral vaccines generates cross-reactive T cells at immunodominant epitopes. The degree of cross-reactivity varies between epitopes and may be HCV-subtype specific.

SUBMITTER: Kelly C 

PROVIDER: S-EPMC4784727 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes.

Kelly Christabel C   Swadling Leo L   Brown Anthony A   Capone Stefania S   Folgori Antonella A   Salio Mariolina M   Klenerman Paul P   Barnes Eleanor E  

European journal of immunology 20141030 1


Viral diversity is a challenge to the development of a hepatitis C virus (HCV) vaccine. Following vaccination of humans with adenoviral vectors, we determined the capacity of T cells to target common viral variants at immundominant epitopes ex vivo. We identified two major variants for epitopes NS3(1073) and NS3(1446), and multiple variants for epitope NS3(1406) that occurred in >5% of genotype 1 and 3 sequences at a population level. Cross-reactivity of vaccine-induced T cells was determined us  ...[more]

Similar Datasets

| S-EPMC5766511 | biostudies-literature
| S-EPMC114725 | biostudies-literature
| S-EPMC5918137 | biostudies-literature
| S-EPMC4524240 | biostudies-literature
| S-EPMC10497216 | biostudies-literature
| S-EPMC8283330 | biostudies-literature
| S-EPMC4682406 | biostudies-other
| S-EPMC4682370 | biostudies-literature
| S-EPMC8302445 | biostudies-literature
| S-EPMC7350033 | biostudies-literature